Yes—multiple sclerosis itself modestly raises susceptibility to certain infections, and some disease-modifying therapies raise it substantially more. The disease chronically activates immune cells that then overshoot into surrounding tissue, while many MS drugs deliberately suppress the same defenses that clear pathogens. The net risk depends on which mechanism dominates: the disease, the drug, or the person.

MS is not a deficiency of immunity. It is a misdirection of it. Autoreactive T cells and B cells cross the blood-brain barrier, attack myelin, and leave behind a chronic inflammatory state. That constant activation exhausts and distorts normal immune signaling. The result is a body that is simultaneously over-reactive against itself and under-effective against some outside threats.

This explainer separates three things people routinely conflate: the infection risk from MS biology, the risk from immunosuppressive treatment, and the risk from common complications like bladder dysfunction. Each has different numbers, different timing, and different practical responses. Getting the distinctions right is what changes outcomes.

The mechanism: chronic immune activation without immune deficiency

The core problem in MS is a targeting error. T helper cells that should recognize foreign antigens instead react to myelin proteins. These cells produce inflammatory cytokines, recruit macrophages, and drive B cells to make antibodies against the nervous system. This is why MS flares produce demyelinating lesions rather than infections.

That sustained inflammatory tone has a cost. chronically elevated cytokines such as tumor necrosis factor and interleukin-17 impair the normal coordination between innate and adaptive immunity. Neutrophils and natural killer cells—the first responders to bacterial and viral invaders—function less efficiently when bathed in constant inflammatory signaling. The immune system is busy, but not productively busy.

A second mechanism is bystander activation. When the immune system is chronically primed, unrelated pathogens can trigger exaggerated or misdirected responses. This is one reason infections sometimes precede MS relapses. The immune system does not neatly separate "attack myelin" from "attack virus"; the activation bleeds across targets.

A third mechanism is structural, not immunological. MS frequently causes bladder dysfunction and reduced mobility. Urinary retention breeds bacterial growth. Reduced coughing and mobility raise pneumonia risk. These are mechanical infection pathways that have nothing to do with immune suppression, and they matter more than most people expect.

How large is the risk, and for whom

The excess infection risk from MS biology alone is real but moderate. Large cohort studies consistently find that people with MS are hospitalized for infections at higher rates than matched controls, with the gap widening as disability progresses. The strongest signals appear for respiratory infections, urinary tract infections, and skin infections.

Treatment changes the picture dramatically. Anti-CD20 therapies such as rituximab and ocrelizumab deplete B cells and are associated with increased risk of respiratory and urinary infections. Fingolimod and related sphingosine-1-phosphate modulators reduce circulating lymphocytes and carry labeled warnings about serious infections, including herpes viruses. Alemtuzumab causes prolonged lymphopenia and requires antiviral prophylaxis.

The pattern is not uniform. Interferon beta and glatiramer acetate, the older injectables, show little to no meaningful increase in serious infection risk. The risk stratifies by mechanism: drugs that deplete or trap immune cells raise infection rates; drugs that modulate signaling without depletion largely do not.

Timing matters too. Infection risk is highest in the months after starting a lymphocyte-depleting agent and during periods of prolonged low lymphocyte counts. Risk also rises with age, with cumulative disability, and with combination immunosuppression. A 30-year-old on interferon faces a very different risk profile than a 60-year-old on a B-cell depleter with a neurogenic bladder.

A counterintuitive detail: MS may protect against some infections

The chronic inflammatory state is not purely harmful to host defense. Some epidemiological data suggest people with MS have lower rates of certain parasitic and intracellular infections, possibly because a hyperactive Th1/Th17 axis clears these pathogens efficiently. This is the hygiene-hypothesis flip side: an immune system tuned too high against internal targets may also be tuned high against some external ones.

The practical caveat is that this protection is inconsistent and should never be relied upon. The dominant clinical reality is that MS plus immunosuppressive treatment plus disability-related complications equals net increased risk for the infections that actually cause harm: pneumonia, sepsis, urinary sources, and herpes reactivation. The protective signal is a biological curiosity, not a clinical reassurance.

Comparison: infection risk by treatment class

Treatment class Main mechanism Serious infection signal Key caveat
Interferon beta, glatiramer Immune modulation, no depletion Minimal increase Long safety record
Sphingosine-1-phosphate modulators Lymphocyte trapping Increased, including herpes First-dose cardiac monitoring
Anti-CD20 (rituximab, ocrelizumab) B-cell depletion Increased respiratory and urinary infections Risk rises with low immunoglobulin
Alemtuzumab Profound lymphocyte depletion Increased; requires antiviral prophylaxis Prolonged lymphopenia
Natalizumab Blocks lymphocyte migration Generally modest PML risk from JC virus, not routine infection

Note that natalizumab's headline risk is not ordinary infection but progressive multifocal leukoencephalopathy, an opportunistic brain infection from JC virus reactivation. This is a distinct category. It is not a sign of broad immune failure; it is a targeted vulnerability from blocking immune cell trafficking into the central nervous system.

Timeline: when vulnerability peaks

Phase Approximate timing What drives risk
Before diagnosis Months to years Active inflammation, diagnostic delay
First months on depleting therapy 0–6 months Falling lymphocyte counts
Maintenance on B-cell depleters 6 months onward Sustained B-cell depletion
Prolonged lymphopenia Variable, sometimes years Cumulative immune suppression
During relapse treatment Days to weeks High-dose corticosteroids
Advanced disability Years after onset Bladder, mobility, aspiration
After stopping depleting drug Months Slow immune reconstitution

High-dose corticosteroids used for relapses deserve their own line. A course of intravenous methylprednisolone transiently raises blood glucose, disrupts sleep, and modestly increases infection risk in the weeks that follow. This is short-lived but real, and it stacks on top of any baseline therapy.

Practical actions and red-flag warnings

Protective steps are concrete. Vaccination status should be reviewed before starting any depleting therapy, because live vaccines are contraindicated during and after suppression and because response to vaccines is weaker once B cells are depleted. Inactivated vaccines—influenza, pneumococcal, COVID-19, shingles—should be completed beforehand where possible.

Get vaccinated before starting immunosuppressive MS therapy, not after. Treat urinary symptoms early; retention and frequency signal possible infection. Seek care for fever above 100.4°F (38°C) that lasts more than a day, especially on depleting therapy. Report new shortness of breath, confusion, or rash promptly—these can signal sepsis or herpes reactivation. Ask about immunoglobulin levels if on long-term anti-CD20 therapy and infections recur. Avoid live vaccines during and after lymphocyte-depleting treatment.

Thresholds worth reconciling: a single fever of 100.4°F is the standard clinical trigger for evaluation, not 101°F or higher. Lymphocyte counts below 0.5 × 10⁹/L are generally considered the zone of meaningful concern for opportunistic infection, while counts between 0.5 and 0.8 warrant monitoring rather than alarm. These are general reference points, not individualized rules—your neurologist's thresholds may differ based on your drug and history.

What the evidence cannot tell you

The honest limitation is that most MS infection data come from observational cohorts, not randomized trials designed to measure infection outcomes. Confounding is substantial: people with more disability get more infections and also tend to be on more potent therapy. Untangling drug effect from disease effect from lifestyle is difficult.

Absent from the evidence is a reliable way to predict which individual on a given drug will develop a serious infection. Lymphocyte counts help but do not fully capture functional immune competence. Immunoglobulin levels help but are not routinely monitored. The field lacks a validated risk score for MS patients.

What can be concluded is directional and practical. MS biology alone modestly increases infection susceptibility through chronic inflammation and disability-related complications. Immunosuppressive therapies increase it further, with the magnitude depending on whether the drug depletes or merely modulates immune cells. Vaccination timing, early symptom reporting, and attention to bladder and respiratory health are the levers that most reliably reduce risk. The disease changes the terrain; the treatment choices and preventive habits determine how much that terrain matters.